Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 322917
                    [Title] => Pinoy docs in most extensive anti-blood clot clinical trial
                    [Summary] => Boehringer-Ingelheim has launched the biggest ever thromboembolic disease clinical trial program. 


The trials under the umbrella name RE-VOLUTION and involving more than 27,000 patients worldwide, will investigate a novel oral direct thrombin inhibitor, dabigatran etexilate, researched and developed by the Germany-based pharmaceutical company to prevent and treat thromboembolic disease.


Dabigatran etexilate is a promising new oral direct thrombin inhibitor that specifically and reversibly inhibits thrombin, the key enzyme for blood clot formation. 


                    [DatePublished] => 2006-02-23 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

LARS WALLENTIN

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 322917
                    [Title] => Pinoy docs in most extensive anti-blood clot clinical trial
                    [Summary] => Boehringer-Ingelheim has launched the biggest ever thromboembolic disease clinical trial program. 


The trials under the umbrella name RE-VOLUTION and involving more than 27,000 patients worldwide, will investigate a novel oral direct thrombin inhibitor, dabigatran etexilate, researched and developed by the Germany-based pharmaceutical company to prevent and treat thromboembolic disease.


Dabigatran etexilate is a promising new oral direct thrombin inhibitor that specifically and reversibly inhibits thrombin, the key enzyme for blood clot formation. 


                    [DatePublished] => 2006-02-23 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Pinoy docs in most extensive anti-blood clot clinical trial

February 23, 2006 - 12:00am

Boehringer-Ingelheim has launched the biggest ever thromboembolic disease clinical trial program. The trials under the umbrella name RE-VOLUTION and involving more than 27,000 patients worldwide, will investigate...

Science and Environment